$4.995
+0.066 (+1.32%)Zum Schluss
CSBR-News
CSBR-Events
Champions Oncology Expands Radiopharmaceutical Development Platform
Champions Oncology announced the expansion of its integrated radiopharmaceutical development platform with new in-house SPECT/CT imaging capabilities. This capability extends Champions' existing radiopharmaceutical services across radiolabeling, biodistribution, efficacy and clinically relevant oncology models. Researchers can now longitudinally visualize and quantify radiopharmaceutical uptake in vivo, and connect those findings with terminal biodistribution, therapeutic response and the molecular characteristics of the tumor model.
Company Reports Q4 Revenue of $13.8M
Reports Q4 revenue $13.8M vs. $12.4M last year. The company noted that a reduction in the cost of oncology revenue reflected continued cost discipline, lower outsourced research services expenses, and lower compensation expense, which generated improved operating leverage and increased the oncology services margin to 51% from 41%. "Fiscal 2026 marked a year of meaningful progress in executing our strategic priorities as we delivered record annual revenue while continuing to invest in the capabilities we believe will support our next phase of growth," said CEO Robert Brainin.
Champions Oncology appoints Rob Brainin as CEO
Champions Oncology announced that its Board of Directors has appointed Rob Brainin as CEO and member of the Board of Directors, effective August 25, 2025. Rob, who has served on Champions' Board since 2021, will succeed Dr. Ronnie Morris, who has led the company as CEO since 2017. Dr. Morris will transition to the role of Executive Chair on August 25, supporting the leadership transition while remaining actively involved in the company's strategic initiatives. Brainin most recently served as Chief Business Officer at Veracyte.
Champions Oncology announces launch of radiopharmaceutical services platform
Champions Oncology announced the full commercial launch of its radiopharmaceutical services platform. This milestone follows the expansion of the company's radioactive materials license, the completion of the radiochemistry infrastructure, and the successful screening of more than thirty PDX models in collaboration with pharmaceutical and biotech partners. Champions now offers fully integrated radiopharmaceutical workflows combining in vitro, ex-vivo biodistribution, and therapeutic efficacy studies across a wide range of isotopes. The company's platform is uniquely differentiated by its extensive bank of patient-derived xenograft tumor models, enabling drug developers to evaluate radiolabeled agents in clinically relevant systems.Champions updated radioactive materials license now includes support for ten key isotopes: Lu-177, Ac-225, In-111, Cu-67, Y-90, Pb-212, At-211 Tb-161, Cu-64, and Zr-89. These additions enable a wide range of study designs including radioligand therapy, antibody radionuclide conjugates and theranostic approaches.
Champions Oncology obtains radioactive materials license
Champions Oncology has been granted a license to use radioactive materials in preclinical studies. This approval allows in-house work utilizing a variety of clinically relevant radionuclides, significantly expanding the organization's capabilities in the development and assessment of targeted radiotherapeutics. Through this license, Champions Oncology is now uniquely positioned to integrate under one roof radionuclide-based therapeutic testing with the most clinically relevant bank of patient derived xenograft models.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.